Who Paid My Doc
Ricardo Cigarroa
Cardiovascular Disease Laredo, TX Medical Doctor
NPI 1295774594 CMS profile 58182
1710 E Saunders St, Tower B Fifth Floor, Laredo, TX 78041
General payments
$6,271
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ricardo Cigarroa of Laredo, TX is reported in the CMS Open Payments database as having received $6,271 across 160 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 73rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $453 | 10 | |
| 2024 | General | $632 | 19 | |
| 2023 | General | $353 | 10 | |
| 2022 | General | $931 | 22 | |
| 2021 | General | $1,054 | 44 | |
| 2020 | General | $2,315 | 35 | |
| 2019 | General | $533 | 20 |
Beside peers
- Ricardo Cigarroa
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Ricardo Cigarroa were reported at $453. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Ricardo Cigarroa | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $533 | $450 | $127–$1,392 | $163 |
| 2020 | $2,315 | $242 | $77–$751 | $114 |
| 2021 | $1,054 | $335 | $101–$1,037 | $132 |
| 2022 | $931 | $395 | $121–$1,211 | $149 |
| 2023 | $353 | $443 | $136–$1,283 | $160 |
| 2024 | $632 | $450 | $136–$1,323 | $164 |
| 2025 | $453 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 174 drugsPart D claims
28,428
Drug cost
$1,789,410
Branded share of claims
24.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Entresto Sacubitril/Valsartan | Brand | 359 | $319,210 | |
| Januvia Sitagliptin Phosphate | Brand | 222 | $208,283 | |
| Jardiance Empagliflozin | Brand | 155 | $165,757 | |
| Eliquis Apixaban | Brand | 182 | $151,103 | |
| Xarelto Rivaroxaban | Brand | 166 | $139,683 | |
| Ozempic Semaglutide | Brand | 86 | $95,204 | |
| Verapamil Er Pm Verapamil Hcl | Brand | 279 | $82,791 | |
| Tradjenta Linagliptin | Brand | 89 | $77,706 | |
| Farxiga Dapagliflozin Propanediol | Brand | 50 | $41,736 | |
| Janumet Sitagliptin Phos/Metformin Hcl | Brand | 46 | $39,306 |
The 10 drugs with the highest cost, of 174 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 191 billing codesPaid by Medicare
$1,760,134
Medicare patients
2,797
Services billed
144,425
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 68% | |
| Ischemic heart disease | 63% | |
| Arthritis | 50% | |
| Chronic kidney disease | 40% | |
| Heart failure | 31% | |
| COPD | 22% | |
| Atrial fibrillation | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 406 | 92,100 | $9,403 |
| Vaccine for influenza for injection into muscle 90662 | Office | 143 | 143 | $8,408 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 271 | 25,560 | $2,530 |
| Injection, methylprednisolone acetate, 20 mg J1020 | Office | 121 | 420 | $1,450 |
| Injection, dipyridamole, per 10 mg J1245 | Office | 84 | 354 | $1,047 |
| Vaccine for influenza for administration into muscle, 0.5 ml dosage 90686 | Office | 24 | 24 | $526 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 297 | 496 | $439 |
| Injection, furosemide, up to 20 mg J1940 | Office | 101 | 472 | $183 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
160 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Texas
Ramin Farzaneh-Far
Cardiovascular Disease · Dallas, TX
John Osborne
Cardiovascular Disease · Grapevine, TX
Darren McGuire
Cardiovascular Disease · Dallas, TX
Peter McCullough
Cardiovascular Disease · Dallas, TX
Ann Navar
Cardiovascular Disease · Dallas, TX
Biykem Bozkurt
Cardiovascular Disease · Houston, TX
Related records
Cardiovascular Disease in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.